Switzer Jeffrey A, Hess David C
Curr Atheroscler Rep. 2006 Jul;8(4):337-42. doi: 10.1007/s11883-006-0013-0.
Coronary heart disease (CHD) and stroke share common risk factors and are the leading causes of death and disability in the United States. Although the impact of elevated cholesterol on stroke risk has been disputed, numerous trials using 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) in patients with CHD have demonstrated a significant reduction in stroke incidence as a secondary endpoint. It is likely that statins are pleiotropic in stroke prevention, providing benefits through both cholesterol reduction and cholesterol-independent mechanisms. In this article, we review the relationship between cholesterol and stroke, randomized trials of statins in patients with CHD and high risk for CHD that have assessed stroke risk, and the putative mechanisms of stroke prevention by statins.
冠心病（CHD）和中风有共同的风险因素，是美国死亡和残疾的主要原因。尽管胆固醇升高对中风风险的影响一直存在争议，但在冠心病患者中使用3-羟基-3-甲基戊二酰辅酶A（HMG CoA）还原酶抑制剂（即他汀类药物）的众多试验已证明，作为次要终点，中风发病率显著降低。他汀类药物在预防中风方面可能具有多效性，通过降低胆固醇和非胆固醇依赖机制发挥益处。在本文中，我们综述了胆固醇与中风之间的关系、在冠心病患者和具有冠心病高风险且评估了中风风险的患者中进行的他汀类药物随机试验，以及他汀类药物预防中风的假定机制。
